| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 19417445
[patent_doc_number] => 20240293568
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 18/651734
[patent_app_country] => US
[patent_app_date] => 2024-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18651734
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/651734 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy | Apr 30, 2024 | Issued |
Array
(
[id] => 19431075
[patent_doc_number] => 20240299573
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 18/629444
[patent_app_country] => US
[patent_app_date] => 2024-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 109027
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629444
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/629444 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | Apr 7, 2024 | Pending |
Array
(
[id] => 20143982
[patent_doc_number] => 12378309
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease
[patent_app_type] => utility
[patent_app_number] => 18/593157
[patent_app_country] => US
[patent_app_date] => 2024-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 2202
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593157
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/593157 | Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease | Feb 29, 2024 | Issued |
Array
(
[id] => 19248766
[patent_doc_number] => 20240199753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => ANTI-IL-11RA ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/590853
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34976
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590853
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/590853 | Anti-interleukin-11 receptor subunit a (IL-11Ra) antibodies | Feb 27, 2024 | Issued |
Array
(
[id] => 19234046
[patent_doc_number] => 20240191238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/587147
[patent_app_country] => US
[patent_app_date] => 2024-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18587147
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/587147 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS | Feb 25, 2024 | Pending |
Array
(
[id] => 19345244
[patent_doc_number] => 20240254207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/584654
[patent_app_country] => US
[patent_app_date] => 2024-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54476
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584654
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/584654 | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF | Feb 21, 2024 | Abandoned |
Array
(
[id] => 19785593
[patent_doc_number] => 20250059272
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => Compositions and Methods for Targeting Connexin Hemichannels
[patent_app_type] => utility
[patent_app_number] => 18/583340
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583340
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/583340 | Compositions and Methods for Targeting Connexin Hemichannels | Feb 20, 2024 | Pending |
Array
(
[id] => 19333660
[patent_doc_number] => 20240248090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => THIOREDOXIN 1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO
[patent_app_type] => utility
[patent_app_number] => 18/443945
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18451
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443945
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443945 | Monoclonal antibody specifically binding to thioredoxin 1 and methods of use thereof for breast cancer diagnosis | Feb 15, 2024 | Issued |
Array
(
[id] => 19235021
[patent_doc_number] => 20240192215
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => THIOREDOXIN 1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO
[patent_app_type] => utility
[patent_app_number] => 18/443970
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18437
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443970
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443970 | Monoclonal antibody specifically binding to thioredoxin 1 and methods of use thereof for breast cancer diagnosis | Feb 15, 2024 | Issued |
Array
(
[id] => 19543204
[patent_doc_number] => 20240360240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1
[patent_app_type] => utility
[patent_app_number] => 18/442906
[patent_app_country] => US
[patent_app_date] => 2024-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41670
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442906
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/442906 | ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1 | Feb 14, 2024 | Abandoned |
Array
(
[id] => 19345249
[patent_doc_number] => 20240254212
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/437617
[patent_app_country] => US
[patent_app_date] => 2024-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437617
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/437617 | Connexin 43 (Cx43) hemichannel-binding antibodies | Feb 8, 2024 | Issued |
Array
(
[id] => 19809529
[patent_doc_number] => 12240900
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-03-04
[patent_title] => Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
[patent_app_type] => utility
[patent_app_number] => 18/431764
[patent_app_country] => US
[patent_app_date] => 2024-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 12975
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431764
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/431764 | Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha | Feb 1, 2024 | Issued |
Array
(
[id] => 19447433
[patent_doc_number] => 20240307563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING
[patent_app_type] => utility
[patent_app_number] => 18/400943
[patent_app_country] => US
[patent_app_date] => 2023-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18400943
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/400943 | RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING | Dec 28, 2023 | Pending |
Array
(
[id] => 19097832
[patent_doc_number] => 20240117060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => ANTI-GLP1R ANTAGONIST ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/542929
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542929
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/542929 | Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies | Dec 17, 2023 | Issued |
Array
(
[id] => 19300084
[patent_doc_number] => 20240228653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => PSGL-1 Antagonists and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/543912
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543912
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/543912 | PSGL-1 Antagonists and Uses Thereof | Dec 17, 2023 | Pending |
Array
(
[id] => 19279893
[patent_doc_number] => 20240216365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/542451
[patent_app_country] => US
[patent_app_date] => 2023-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11835
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542451
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/542451 | METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS | Dec 14, 2023 | Abandoned |
Array
(
[id] => 20453059
[patent_doc_number] => 12516109
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Composition comprising anti-gliadin antibodies and method of use thereof to detect gliadin in a sample
[patent_app_type] => utility
[patent_app_number] => 18/538748
[patent_app_country] => US
[patent_app_date] => 2023-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8901
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538748
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/538748 | Composition comprising anti-gliadin antibodies and method of use thereof to detect gliadin in a sample | Dec 12, 2023 | Issued |
Array
(
[id] => 20309224
[patent_doc_number] => 20250326853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-23
[patent_title] => FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/535068
[patent_app_country] => US
[patent_app_date] => 2023-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18535068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Dec 10, 2023 | Pending |
Array
(
[id] => 20633457
[patent_doc_number] => 12594321
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-07
[patent_title] => Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
[patent_app_type] => utility
[patent_app_number] => 18/529915
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 47
[patent_no_of_words] => 123956
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529915
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/529915 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTORS | Dec 4, 2023 | Issued |
Array
(
[id] => 20187099
[patent_doc_number] => 12398204
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-26
[patent_title] => Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist
[patent_app_type] => utility
[patent_app_number] => 18/528957
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 36
[patent_no_of_words] => 56376
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528957
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/528957 | Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist | Dec 4, 2023 | Issued |